Lung Cancer

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Scarcely a week goes by without a report in the peer-reviewed medical literature suggesting that a novel somatic genomic alteration or a specific normal polymorphism is potentially relevant to achieving a desirable clinical outcome within cancer medicine.

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

A preliminary analysis has shown that eribulin mesylate failed to meet its primary endpoint of improving overall survival in pre-treated patients with advanced non-small cell lung cancer

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

At Memorial Sloan Kettering, we offer a variety of clinical trials for patients with mesothelioma at all stages of their disease.

The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.

Yelena Y. Janjigian, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses results of an early-phase study looking at afatinib and cetuximab for patients with EGFR-mutant lung cancer.

As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Everett E. Vokes, MD, Giant of Cancer Care: Lung Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses PARP inhibitors as treatments for patients with lung cancer.

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.